Related Experiment Video
Updated: Aug 30, 2025
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Enhancing the immune effect of oHSV-1 therapy through TLR3 signaling in uveal melanoma
Sisi Liu1, Mingxin Li2, Fengqiao Sun3
1Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Dongjiao Minxiang 1, Dongcheng District, Beijing, 100730, China.
Purpose:
Uveal melanoma (UM) is the most common primary intraocular malignant tumor in adults, with patients having a low overall survival rate. Oncolytic viruses (OVs) have been shown effective as monotherapy or combined with immunotherapy in the treatment of UM. Oncolytic herpes simplex type I virus (oHSV-1) was found to alter gene expression and immune function in UMs. We investigated whether a combination treatment would be more effective in treating UM and reactive immune cells.
Methods:
RNA sequencing analysis were used to identify the effect of oHSV-1 infection in UM cells and protein changes were validated by western blot. Cell viability assays were performed through UM cell lines (MUM2B, 92.1, and MP41) and retinal pigment epithelial cell line (ARPE-19) to identify the efficacy and safety of the combination treatment. Western blot, qRT-PCR, cell viability assay and immunocytochemistry were performed to discover the reactivation of immune cells (U937 and HMC3).
Results:
Through RNA sequencing analysis and in vitro molecular biology assays, this study tested the ability of oHSV-1 combined with the TLR3 agonist poly(I:C) to re-activate the TLR3 meditated NF-ƙB signaling pathway and further increase the anti-tumor activity of UM cells and macrophages, including the stimulation of macrophage polarization and proliferation.
Conclusions:
These findings indicate that the treatment of UM with a combination of oHSV-1 and poly(I:C) generates immune responses and enhances anti-tumoral activity, suggesting the need for further investigations and clinical trials of this combination.
Insights
Combining oncolytic herpes simplex type I virus (oHSV-1) with poly(I:C) enhances anti-tumor activity in uveal melanoma (UM) by reactivating immune cells. This combination therapy shows promise for treating UM and improving patient survival rates.
Area of Science:
- Oncology
- Virology
- Immunology
Background:
- Uveal melanoma (UM) is a prevalent intraocular malignancy with poor survival rates.
- Oncolytic viruses (OVs), particularly oncolytic herpes simplex type I virus (oHSV-1), demonstrate potential in UM treatment, alone or with immunotherapy.
- oHSV-1 influences gene expression and immune function in UM.
Purpose of the Study:
- To investigate the efficacy of a combination treatment for UM and reactive immune cells.
- To evaluate the combined effect of oHSV-1 and poly(I:C) on UM and immune cells.
Main Methods:
- RNA sequencing and western blot to analyze oHSV-1 effects on UM cells.
- Cell viability assays using UM and retinal pigment epithelial cell lines to assess treatment safety and efficacy.
- Western blot, qRT-PCR, and immunocytochemistry to study immune cell reactivation.
Main Results:
- The combination of oHSV-1 and poly(I:C) reactivates the TLR3-mediated NF-κB signaling pathway.
- This combination enhances anti-tumor activity in UM cells and macrophages.
- Macrophage polarization and proliferation are stimulated by the combined treatment.
Conclusions:
- Combination therapy with oHSV-1 and poly(I:C) elicits immune responses and boosts anti-tumoral activity in UM.
- Further research and clinical trials are warranted to explore this combination therapy for UM treatment.
